|
04-05-2010, 12:29 PM
|
|||
|
|||
US FDA seeks additional data from ProStrakans Rectogesic NDA
ProStrakan Group plc, the international specialty pharmaceutical company, announces that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) for its New Drug Application for Rectogesic (0.4% nitroglycerin ointment) for the treatment of pain associated with chronic anal fissures.
    
|
 |
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Accused cancer faker faces additional charge | cancerfr | Ovarian Cancer | 0 | 08-13-2010 03:59 AM |
| Additional Benefits of Selenium | cancerfr | Discuss Holistic Treatments | 1 | 04-09-2010 06:20 AM |
| (AFX UK Focus) 2010-04-01 08:30 UPDATE 1-ProStrakan says FDA seeks more data on pain | cancerfr | Anal cancer | 0 | 04-01-2010 10:36 AM |
| pSivida Reports Presentation of Additional Positive 24-Month Data from Iluvien Phase | cancerfr | AIDS-related cancer | 0 | 04-01-2010 04:05 AM |
| Chugai Pharma seeks Japanese additional approval for anti-cancer agents Herceptin & X | cancerfr | Oral Cancer | 0 | 03-21-2010 11:40 AM |
Linear Mode
